High-cost drugs in ophthalmology      

FOI REFERENCE: 24450  FOI DATE: 17^th October 2024       

I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following question will be highly appreciated. 

For the 4 months from May to August 2024, how many unique patients received the following intra-vitreal treatments for any eye condition:

Aflibercept                                          1552

Bevacizumab                                      94

Brolucizumab                                     0

Dexamethasone                                 110

Faricimab                                           282

Ranibizumab – Lucentis                     7

Ranibizumab – Ongavia                     335

Ranibizumab – Ximluci                       0